Top 10: Takeda's late-stage pipeline will re­ly heav­i­ly on Shire drugs — but is it worth $62B?

If you’re look­ing for some sol­id rea­sons for Take­da CEO Christophe We­ber’s re­lent­less pur­suit of a $62 bil­lion Shire buy­out, you need look no fur­ther than the Japan-based com­pa­ny’s Q2 num­bers. 

Take­da just post­ed its weak­est sec­ond quar­ter num­bers in three years, with prof­its down by half. And an­a­lysts are not hap­py with Take­da’s late-stage pipeline. So how does it make up for its poor R&D per­for­mance? 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.